| abstract |
The invention is directed to substituted indoline derivatives; specifically, the invention is directed to compounds according to formula I: (See Formula) in which R1, R2 and R3 are defined herein; The compounds of the invention are PERK inhibitors and may be useful in the treatment of cancer, eye diseases and diseases associated with the response pathways to activated deployed proteins, such as Alzheimer's disease, stroke, type 1 diabetes, disease. Parkinson's, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis and arrhythmias, and more specifically breast, colon, pancreatic and pulmonary cancers; therefore, the invention is further directed to pharmaceutical compositions comprising a compound of the invention; The invention is further directed to methods for inhibiting PERK activity, and to treating disorders associated therewith, using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. |